smaller incision, new generation implantable miniature telescope (SING-IMT)
DeviceThe IMT (model SING) is an intraocular implant comprised of 2 micro lenses in a glass tube (optics) in a flexible silicone carrier (haptics)
NCT Number: NCT05438732
The objective of this study is to determine the safety and effectiveness of the smaller incision, new generation (SING), implantable miniature telescope (IMT) in patients with moderate-severe central vision loss due to late-stage age-related macular degeneration (AMD).
Interested in participating?
Request Info65 year and older
All sexes
Interventional
Not applicable
Loma Linda University, Loma Linda, California, United States
Following completion of informed consent, patients will be evaluated for eligibility to enroll into the study, including assessment of their best-corrected distance- and near- visual acuity with and without refraction, and also when using an external telescope simulator (ETS) to determine if they are likely to benefit from receiving the IMT. If eligible, they will be scheduled for out-patient surgery to implant the IMT during routine cataract surgery. Following implantation, patients will return for 5 post-operative follow-up visits over a period of approximately 12 months. Additionally, patients will have up to 12 rehabilitation/training visits with a low vision specialist
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
For the Implanted Eye:
For the Non-Implanted Eye:
Exclusion criteria
For the Implanted Eye:
For the Non-Implanted Eye:
The IMT (model SING) is an intraocular implant comprised of 2 micro lenses in a glass tube (optics) in a flexible silicone carrier (haptics)
Time frame: Approximately 12-months post-operatively (330-420 days)
Proportion of study eyes with an improvement of 10 or more ETDRS letters (0.2 logMAR) in either BCDVA or BCNVA at Visit 5 (330 to 420 days post-operatively) compared to Pre-operative Visit
Time frame: Approximately 12-months post-operatively (330-420 days)
Percent change in endothelial cell density (ECD) from Pre-operative Visit in study eyes at Visit 5 (330 to 420 days post-operatively)
Time frame: Approximately 12-months post-operatively (330-420 days)
Post-operative BCDVA in study eyes at Visit 5 (330 to 420 days post-operatively) compared to Pre-operative Visit
Time frame: Approximately 12-months post-operatively (330-420 days)
Post-operative BCNVA in study eyes at Visit 5 (330 to 420 days post-operatively) compared to Pre-operative Visit
Time frame: Approximately 12-months post-operatively (330-420 days)
Anterior Chamber Depth in study eyes, defined as the distance between the corneal endothelium and the front surface of the IMT, at Visit 5 (330 to 420 days post-operatively)
Time frame: Approximately 12-months post-operatively (330-420 days)
IMT tilt and centration in study eyes at Visit 5 (330 to 420 days post-operatively)
Time frame: Approximately 12-months post-operatively (330-420 days)
Rates of adverse events from Operative Visit through Visit 5 (330 to 420 days post-operatively)
Time frame: Approximately 12-months post-operatively (330-420 days)
Rates of posterior capsule opacification in study eyes at post-operative visit 5 (330 to 420 days post-operatively)
Contact information is provided by the study sponsor or research team.
Colleen Collier
CONTACT
Rebecca Kammer, OD, PhD
CONTACT
VisionCare, Inc.
Industry
A Prospective, Multicenter Clinical Study of the Implantable Miniature Telescope, Model SING in Patients with Central Vision Impairment Associated with End-stage Age-related Macular Degeneration (AMD)
Acronym: CONCERTO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07160179
Age-Related Macular Degeneration, Eye Diseases
Carmel, Indiana, United States
View Trial DetailsNCT01866371
Age-Related Macular Degeneration, Choroid Diseases
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT07556406
Age-Related Macular Degeneration, Eye Diseases
San Francisco, California, United States
View Trial DetailsNCT06087458
Age-Related Macular Degeneration, Eye Diseases
Scottsdale, Arizona, United States
View Trial Details